These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

263 related articles for article (PubMed ID: 24345883)

  • 21. Combined inhibition of EZH2 and histone deacetylases as a potential epigenetic therapy for non-small-cell lung cancer cells.
    Takashina T; Kinoshita I; Kikuchi J; Shimizu Y; Sakakibara-Konishi J; Oizumi S; Nishimura M; Dosaka-Akita H
    Cancer Sci; 2016 Jul; 107(7):955-62. PubMed ID: 27116120
    [TBL] [Abstract][Full Text] [Related]  

  • 22. EZH2 inhibitors reverse resistance to gefitinib in primary EGFR wild-type lung cancer cells.
    Gong H; Li Y; Yuan Y; Li W; Zhang H; Zhang Z; Shi R; Liu M; Liu C; Chen C; Liu H; Chen J
    BMC Cancer; 2020 Dec; 20(1):1189. PubMed ID: 33276757
    [TBL] [Abstract][Full Text] [Related]  

  • 23. EZH2-mediated inactivation of IFN-γ-JAK-STAT1 signaling is an effective therapeutic target in MYC-driven prostate cancer.
    Wee ZN; Li Z; Lee PL; Lee ST; Lim YP; Yu Q
    Cell Rep; 2014 Jul; 8(1):204-16. PubMed ID: 24953652
    [TBL] [Abstract][Full Text] [Related]  

  • 24. EZH2 modulates angiogenesis in vitro and in a mouse model of limb ischemia.
    Mitić T; Caporali A; Floris I; Meloni M; Marchetti M; Urrutia R; Angelini GD; Emanueli C
    Mol Ther; 2015 Jan; 23(1):32-42. PubMed ID: 25189741
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Inhibition enhancer of zeste homologue 2 promotes senescence and apoptosis induced by doxorubicin in p53 mutant gastric cancer cells.
    Bai J; Ma M; Cai M; Xu F; Chen J; Wang G; Shuai X; Tao K
    Cell Prolif; 2014 Jun; 47(3):211-8. PubMed ID: 24738879
    [TBL] [Abstract][Full Text] [Related]  

  • 26. EZH2 overexpression in natural killer/T-cell lymphoma confers growth advantage independently of histone methyltransferase activity.
    Yan J; Ng SB; Tay JL; Lin B; Koh TL; Tan J; Selvarajan V; Liu SC; Bi C; Wang S; Choo SN; Shimizu N; Huang G; Yu Q; Chng WJ
    Blood; 2013 May; 121(22):4512-20. PubMed ID: 23529930
    [TBL] [Abstract][Full Text] [Related]  

  • 27. The polycomb group protein enhancer of zeste 2 is a novel therapeutic target for cervical cancer.
    Ding M; Zhang H; Li Z; Wang C; Chen J; Shi L; Xu D; Gao Y
    Clin Exp Pharmacol Physiol; 2015 May; 42(5):458-64. PubMed ID: 25739318
    [TBL] [Abstract][Full Text] [Related]  

  • 28. H2AK119Ub1 and H3K27Me3 in molecular staging for survival prediction of patients with pancreatic ductal adenocarcinoma.
    Chen S; Chen J; Zhan Q; Zhu Y; Chen H; Deng X; Hou Z; Shen B; Chen Y; Peng C
    Oncotarget; 2014 Nov; 5(21):10421-33. PubMed ID: 25431952
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Analysis of the antiproliferative effects of 3-deazaneoplanocin A in combination with standard anticancer agents in rhabdoid tumor cell lines.
    Unland R; Borchardt C; Clemens D; Kool M; Dirksen U; Frühwald MC
    Anticancer Drugs; 2015 Mar; 26(3):301-11. PubMed ID: 25415657
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Genetic or pharmacologic blockade of enhancer of zeste homolog 2 inhibits the progression of peritoneal fibrosis.
    Shi Y; Tao M; Wang Y; Zang X; Ma X; Qiu A; Zhuang S; Liu N
    J Pathol; 2020 Jan; 250(1):79-94. PubMed ID: 31579944
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Enhancer of zeste homolog 2 is overexpressed and contributes to epigenetic inactivation of p21 and phosphatase and tensin homolog in B-cell acute lymphoblastic leukemia.
    Chen J; Li J; Han Q; Sun Z; Wang J; Wang S; Zhao RC
    Exp Biol Med (Maywood); 2012 Sep; 237(9):1110-6. PubMed ID: 22956625
    [TBL] [Abstract][Full Text] [Related]  

  • 32. EZH2 inhibition enhances the efficacy of an EGFR inhibitor in suppressing colon cancer cells.
    Katona BW; Liu Y; Ma A; Jin J; Hua X
    Cancer Biol Ther; 2014; 15(12):1677-87. PubMed ID: 25535899
    [TBL] [Abstract][Full Text] [Related]  

  • 33. S-Adenosyl-L-methionine-competitive inhibitors of the histone methyltransferase EZH2 induce autophagy and enhance drug sensitivity in cancer cells.
    Liu TP; Lo HL; Wei LS; Hsiao HH; Yang PM
    Anticancer Drugs; 2015 Feb; 26(2):139-47. PubMed ID: 25203626
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Methyl jasmonate sensitizes human bladder cancer cells to gambogic acid-induced apoptosis through down-regulation of EZH2 expression by miR-101.
    Wang Y; Xiang W; Wang M; Huang T; Xiao X; Wang L; Tao D; Dong L; Zeng F; Jiang G
    Br J Pharmacol; 2014 Feb; 171(3):618-35. PubMed ID: 24490857
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Targeting EZH2 for cancer therapy: progress and perspective.
    Han Li C; Chen Y
    Curr Protein Pept Sci; 2015; 16(6):559-70. PubMed ID: 25854924
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Dual Inhibition of EZH2 and EZH1 Sensitizes PRC2-Dependent Tumors to Proteasome Inhibition.
    Rizq O; Mimura N; Oshima M; Saraya A; Koide S; Kato Y; Aoyama K; Nakajima-Takagi Y; Wang C; Chiba T; Ma A; Jin J; Iseki T; Nakaseko C; Iwama A
    Clin Cancer Res; 2017 Aug; 23(16):4817-4830. PubMed ID: 28490465
    [No Abstract]   [Full Text] [Related]  

  • 37. Pharmacological inhibition of EZH2 as a promising differentiation therapy in embryonal RMS.
    Ciarapica R; Carcarino E; Adesso L; De Salvo M; Bracaglia G; Leoncini PP; Dall'agnese A; Verginelli F; Milano GM; Boldrini R; Inserra A; Stifani S; Screpanti I; Marquez VE; Valente S; Mai A; Puri PL; Locatelli F; Palacios D; Rota R
    BMC Cancer; 2014 Feb; 14():139. PubMed ID: 24575771
    [TBL] [Abstract][Full Text] [Related]  

  • 38. VEGF/VEGFR-2 upregulates EZH2 expression in lung adenocarcinoma cells and EZH2 depletion enhances the response to platinum-based and VEGFR-2-targeted therapy.
    Riquelme E; Suraokar M; Behrens C; Lin HY; Girard L; Nilsson MB; Simon G; Wang J; Coombes KR; Lee JJ; Hong WK; Heymach J; Minna JD; Wistuba II
    Clin Cancer Res; 2014 Jul; 20(14):3849-61. PubMed ID: 24850841
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Selective inhibition of EZH2 by ZLD1039 blocks H3K27 methylation and leads to potent anti-tumor activity in breast cancer.
    Song X; Gao T; Wang N; Feng Q; You X; Ye T; Lei Q; Zhu Y; Xiong M; Xia Y; Yang F; Shi Y; Wei Y; Zhang L; Yu L
    Sci Rep; 2016 Feb; 6():20864. PubMed ID: 26868841
    [TBL] [Abstract][Full Text] [Related]  

  • 40. ZMYND8 preferentially binds phosphorylated EZH2 to promote a PRC2-dependent to -independent function switch in hypoxia-inducible factor-activated cancer.
    Tang B; Sun R; Wang D; Sheng H; Wei T; Wang L; Zhang J; Ho TH; Yang L; Wei Q; Huang H
    Proc Natl Acad Sci U S A; 2021 Feb; 118(8):. PubMed ID: 33593912
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 14.